转化医学

订阅

MedSci主页 / 所有栏目 / 转化医学

Clinica Chimica Acta：开发和验证LC-MS/MS新方法对血清雌二醇进行定量

2019-08-08 不详 MedSci原创

血清雌二醇
关注

在开发免疫分析方法之前，对于雌二醇的测定方法一直采用气相色谱<span lang="EN-US" style="font-size:12.0pt;mso-bidi-font-size:14.0pt;font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;; mso-fareast-font-family:宋体;mso-bidi-font-fam

在开发免疫分析方法之前，对于雌二醇的测定方法一直采用气相色谱-质谱联用技术。虽然免疫测定速度快，需要的样本量小，但它也存在特异性问题。近年来，液相色谱-串联质谱联用已成为测定血清雌二醇的首选方法。然而，这类所有方法的一个共同点，那就是缺乏标准化。

在此，研究人员建立了LC-MS/MS分析方法，并使用标准测量程序指定的浓度校准器进行了临床验证，以提高校准的准确性。结果显示，以200微升血清为研究对象，采用正己烷-乙酸乙酯萃取液-液萃取，然后用氯化丹酰衍生化。梯度洗脱的运行时 6.5分钟。分析测量范围是2到1000 pg / mL，分析间不精确的< 10%。研究显示，通过与两个参考实验室的比较，发现偏差可接受，来自欧盟委员会联合研究中心、参考材料与研究所和美国病理学家精确调查样本学院的参考材料测量也是如此。

本研究建立了血清雌二醇的LC-MS/MS测定方法，并利用CDC RMP指定的校准浓度进行了临床验证，以帮助提高准确度。

原始出处：

JustinDowis,Witold Woroniecki,Development and validation of a LC-MS/MS assay for quantification of serum estradiol using calibrators with values assigned by the CDC reference measurement procedure

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1849677, encodeId=a55a18496e728, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 11 15:21:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903376, encodeId=2a0b19033e696, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Dec 17 16:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299420, encodeId=3c97129942071, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sat Aug 10 06:21:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-10-11 windight

    #CTA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1849677, encodeId=a55a18496e728, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 11 15:21:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903376, encodeId=2a0b19033e696, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Dec 17 16:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299420, encodeId=3c97129942071, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sat Aug 10 06:21:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-12-17 kord1982

    #新方法#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1849677, encodeId=a55a18496e728, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 11 15:21:00 CST 2019, time=2019-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903376, encodeId=2a0b19033e696, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Tue Dec 17 16:21:00 CST 2019, time=2019-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299420, encodeId=3c97129942071, content=<a href='/topic/show?id=60ea98e5030' target=_blank style='color:#2F92EE;'>#雌二醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98750, encryptionId=60ea98e5030, topicName=雌二醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f9e287, createdName=hxzhang, createdTime=Sat Aug 10 06:21:00 CST 2019, time=2019-08-10, status=1, ipAttribution=)]
    2019-08-10 hxzhang

    #雌二醇#

    0

相关资讯

Hum Reprod Update：CA125对先兆流产结局的预示作用高于HCG和孕酮

背景：先兆流产影响1/5的女性，它与情绪困扰有显著相关性。先兆流产的预后仍然不能确定，由此成为了医疗护理专业人员的一项挑战。过去几年已经研究出多种生物标志物以预测先兆流产的结局；然而，结果却十分矛盾。因此，研究人员构建了一项系统性回顾性meta分析，以研究生物标志物在预测先兆流产女性妊娠结局的诊断准确性。方法：这是一项系统回顾性meta分析的前瞻性研究，探究生物标志物预测孕龄在5-23周范围的女性